Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Enveric Biosciences Inc. (ENVB) — CAMBRIDGE, Mass., July 28, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.